EMA — authorised 19 May 2015
- Marketing authorisation holder: Santen Oy
- Status: approved
🇪🇺 Sandimmune in European Union
EMA authorised Sandimmune on 19 May 2015
Marketing authorisation
Sandimmune in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Sandimmune approved in European Union?
Yes. EMA authorised it on 19 May 2015.
Who is the marketing authorisation holder for Sandimmune in European Union?
Santen Oy holds the EU marketing authorisation.